Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305903 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00305903 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 150 participants.
The verdict
NCT00305903, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy. This study is designed to evaluate the safety and tolerability of add on therapy with memantine to rivastigmine capsules in patients with probable AD (MMSE 10-20)
Interventions
- DRUG Rivastigmine, memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305903
The ClinicalTrials.gov registry entry for NCT00305903 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivastigmine, memantine is the first listed.
NCT00305903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305903 about?
NCT00305903 is a clinical study titled "Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease". This is a prospective, 26-week, open-label, single-arm multi-center pilot study. Eligible patients will receive open-label treatment with rivastigmine capsules plus memantine tablets as add on therapy. This study is designed to evaluate the safety and tolerability of add on therapy with memantine to...
What is the current status of trial NCT00305903?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2006-03. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00305903?
The interventions under investigation include: Rivastigmine, memantine (DRUG).
Who is sponsoring clinical trial NCT00305903?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.